🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Immusoft Corporation secures $ 8M from California Institute for Regenerative Medicine to advance the engineered B cell clinical program. The funds will help to initiate a clinical trial for ISP-001, an engineered autologous B-cell therapy intended for the treatment of mucopolysaccharidosis type I. bit.ly/3KleiJf

Genome-editing of primary B cells is becoming increasingly important in this space. It’s exciting to be a scientific advisor to Immusoft, the leader in engineered B cells. @eqxfund Immusoft Corporation #proudinvestor businesswire.com/news/home/2023…

Excited to announce we’ve acquired the exclusive worldwide rights to IP for #genomeediting technology for primary B cells. 🧬🧬🧬 Read the full release: businesswire.com/news/home/2023…

M&A #news ~Immusoft Corporation acquires exclusive, worldwide rights to University of Minnesota's #IP for #genome edited primary B Cells ~#BiminiHealthTech acquires exclusive license to #accellular dermal matrix product portfolio ~Mindstrong sells #tech assets to 333

At this year's ASGCT annual meeting, engineered B cells are shining 🤩 Beautiful abstracts from Paula Cannon Matthew Porteus, Jennifer Adair, @JustinTaylorLab , Hans-Peter Kiem , Richard James and David Rawlings, Immusoft Corporation and Be Biopharma

Great companies, in great company! Honored for Aurion to share BioFuture Stage with Endpoints News [email protected], Sean Ainsworth Immusoft Corporation, Christine Silverstein Excision BioTherapeutics, Liz Wood @JuraBio to talk about the future of cell and gene therapy: how it will transform patient care.

The Westcott family first invested in Immusoft Corporation in 2013 when the idea of genetically engineering B-cells (antibody) was just that…an idea. Ten years later, they have dosed their first patient. One day this technology could change millions of lives. We are proud to have played

Incredibly proud to announce that Immusoft has dosed the first ever patient with an engineered b cell, and with none of the preconditioning or immunosuppression needed for gene modified stem cells or gene therapy. That's huge. wired.com/story/b-cells-…

Engineering B-cells: First in human trial in patient with mucopolysaccharidosis type I Ex vivo B-cell gene engineering to produce missing enzyme by Immusoft Corporation wired.com/story/b-cells-…

Immusoft Begins Clinical Trial of Autologous B-Cell Therapy in Mucopolysaccharidosis Type I. ISP-001, which Immusoft developed using its Immune System Programming platform, aims to reprogram patients' B cells so they keep producing alpha-L-iduronidase. ow.ly/pCGK1055NEQ

.FierceBiotech covers our first patient dosed for the world’s first engineered B cell therapy. 🧬🧬🧬 fiercebiotech.com/biotech/first-…

Emily Mullin, from WIRED, writes:  "Immusoft Corporation announced that its scientists have genetically programmed a patient’s B cells and put them back in his body in an effort to treat disease. It’s the first time engineered B cells have been tested in a person." bit.ly/3RKOj1q

Thanks Inside Precision Medicine for covering our first patient dosed news! insideprecisionmedicine.com/topics/transla…

A trial by Seattle-based Immusoft, a biotech company, said it is the first to genetically engineer B cells and test them in a patient, Wired reported Dec. 15. bit.ly/3TtmJH2

CIRM is proud to support Immusoft Corporation's groundbreaking B cell therapy trial for MPS I and other diseases. "Our goal is always to move the most promising research forward as fast as we can,” said Dr. Abla Creasey, VP of Therapeutics Development at CIRM. wired.com/story/b-cells-…

.Clinical Trials Arena covers our first patient dosed in #MPS1: clinicaltrialsarena.com/news/immusoft-…

.Drug Discovery World covers our recent first patient dosed using the world’s first engineered B cell therapy. 🧬🧬🧬 ddw-online.com/worlds-first-e…

We’re excited to announce our presentation at WORLDSymposia 2024 Conference, held in San Diego, February 4-9. WORLDSymposium is the largest international gathering of lysosomal disease researchers. Read the full release: businesswire.com/news/home/2024…